조기유방암 환자에서 방사선 모의치료 방법의 차이에 따른 심근관류결손의 비교 평가 = Evaluation and Comparison of Myocardial Perfusion Defects in Patients with Early Breast Cancer Subjected to Different Radiation Simulation Techniques

국문 초록 (Abstract)

목 적: 좌측 조기유방암으로 보존수술 후 2차원 또는 3차원 모의치료를 통해 방사선치료를 받은 환자들에서 SPECT (single photon emitted computerized tomography) 영상을 이용하여 심근관류결손의 부위와 빈도를 비교 평 가하고자 하였다. 대상 및 방법: 2002년 1월부터 2003년 8월까지 AJCC 병기 T1-T2N0M0인 좌측 조기유방암으로 진단되어 외과에서 보존수술 및 화학요법 후 방사선치료를 시행하였던 32명의 환자들을 대상으로 하였다. X선 투시기를 이용한 2차원 모의치료를 통해 방사선치료를 받은 환자들과 컴퓨터단층촬영 기반의 3차원 모의치료 방법을 이용했던 환자들을 구분하여 연구를 진행하였다. 이들을 대상으로 최소 3년 이상의 추적관찰 기간 후에 technetium-99m-sestamibi gated perfusion SPECT를 시행하여 각 군에서의 심근관류결손의 부위와 빈도를 비교 평가하였고, 각 환자들에서의 심벽의 운동상태와 좌심실의 박출량을 측정하여 분석하였다. 또한 모의치료 과정에서 방사선에 피폭되는 심장영 역을 각 군에서 측정하여 심근관류결손과의 상관관계를 알아보았다. 결 과: SPECT 영상 결과, 심근관류결손이 확인된 경우는 전체 32명의 환자 중 11명(34.4%)이었다. 2차원 모의치료를 받은 15명의 환자 중 7명(46.7%)에서, 3차원 모의치료를 받은 17명의 환자 중 4명(23.5%)에서 관류결손이 발견되었는데, 3차원 모의치료를 이용한 환자들에서 심근관류결손의 빈도가 통계적으로 유의하게 낮았다(p=0.0312). 심근관류결손이 확인된 11명 중, 심첨부 결손을 보인 경우가 10명으로 대부분을 차지했다. 심벽의 운동상태와 심실박출량은 모두 정상이었으며, 방사선 조사야에 포함된 심장영역은 3차원 모의치료 군에서 보다 작았으나 양군에서의 심근관류결손과의 통계적 유의성은 확인할 수 없었다. 결 론: 저자들은 이번 연구를 통해 좌측 조기유방암 환자에서 보존수술 후 방사선치료 시 전산화단층촬영 모의치료기를 이용한 3차원 모의치료 방법을 이용하면 심근에 대한 조사용적을 줄일 수 있어 심근관류결손의 빈도를 낮출 수 있음을 확인하였다. 그러나 심근관류스캔상의 결손과 향후 임상적인 허혈성 심장질환으로의 발전 또는 이로 인한 사망률의 증가와의 연관성은 장기간의 추적관찰과 전향적 임상연구를 통해 확인할 필요가 있겠다.

다국어 초록 (Multilingual Abstract)

P urpose: The aim of this study is to evaluate and compare the incidence and aspects of myocardial perfusion defects in patients who were subjected to either two- dimensional or three- dimensional simulation techniques for early left- sided breast cancer. The myocardial perfusion defects were determined from using single photon emitted computerized tomography (SPECT) myocardial perfusion images. Materials and Methods: Between January 2002 and August 2003, 32 patients were enrolled in this study. The patients were diagnosed as having early (AJCC stage T1- T2N0M0) left- sided breast cancer and were treated with tangential irradiation after breast- conserving surgery and systemic chemotherapy. The patients were divided into two groups according to the type of simulation received: two- dimensional simulation using an X- ray fluoroscope simulator or three- dimensional simulation with a CT simulator. All patients underwent technetium- 99m- sestamibi gated perfusion SPECT at least 3 years after radiotherapy. The incidence and area of myocardial perfusion defects were evaluated and were compared in the two groups, and at the same time left ventricular ejection fraction and cardiac wall motion were also analyzed. The cardiac volume included in the radiation fields was calculated and evaluated to check for a correlation between the amount of irradiated cardiac volume and aspects of myocardial perfusion defects. R esults: A myocardial perfusion defect was detected in 11 of 32 patients (34.4%). There were 7 (46.7%) perfusion defect cases in 15 patients who underwent the two- dimensional simulation technique and 4 (23.5%) patients with perfusion defects in the three- dimensional simulation group (p=0.0312). In 10 of 11 patients who had myocardial perfusion changes, the perfusion defects were observed in the cardiac apex. The left ventricular ejection fraction was within the normal range and cardiac wall motion was normal in all patients. The irradiated cardiac volume of patients in the three- dimensional simulation group was less than that of patients who received the two- dimensional simulation technique, but there was no statistical significance as compared to the incidence of perfusion defects. Conclusion: Radiotherapy with a CT simulator (three- dimensional simulation technique) for early left- sided breast cancer may reduce the size of the irradiated cardiac volume and the incidence of myocardial perfusion defects. Further investigation and a longer follow- up duration are needed to analyze the relationship between myocardial perfusion defects and clinical ischemic heart disease.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과 고안 및 결론

참고문헌 (Reference)

1 "and lipid metabolism in pigeons" 165-177,

2 "The synergism of X-radiation and cholesterol fat feeding on the development of coronary artery lesions" 325-334,

3 "The incidence and functional consequences of RT-associated cardiac perfusion defects" 63 : 214-223, 2005

4 "Studies of the mortality of atomic bomb survivors. Report 12, Part II. Noncancer mortality: 1950-1990" 152 : 374-389, 1999

5 "Postoperative radiotherapy in breast cancer-long-term results from the Oslo study" 727-732,

6 "Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer" 15-29,

7 "Myocardial perfusion changes in patients irradiated for left-sided breast cancer and correlation with coronary artery distribution" 55 : 914-920, 2003

8 "Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study" 36 : 899-905, 1996

9 "Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90000 Swedish women" 326 : 256-257, 2003

10 "Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials" 355 : 1757-1770, 2000

11 "Early cardiac changes related to radiation therapy" 943-946, amjcardiol1985;56

12 "Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy" 64 : 53-63, 2002

13 "Comparison of virtual wedge versus physical wedge affecting on dose distribution of treated breast and adjacent normal tissue for tangential breast irradiation" 22 : 225-233, 2004

14 "Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols" 1155-1157,

15 "Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy" 447-453, jclinoncol1994;12

16 "Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients" 16 : 3493-3501, 1998

17 "Acute cardiac effects of mediastinal irradiation assessment by radionuclide angiography" be (be): 897-903,